Trial Profile
A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary) ; Memantine
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacogenomic
- Acronyms EXPECT
- 19 Jul 2012 Efficacy results presented at the 2012 International Conference on Alzheimer's Disease.
- 12 May 2011 Primary endpoint "retention rate" has been met, according to results published in Current Medical Research and Opinion.
- 12 May 2011 Results published in Current Medical Research and Opinion.